|Day Low/High||4.18 / 4.30|
|52 Wk Low/High||4.18 / 65.96|
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its fourth quarter and full year 2016 financial and operating results on Tuesday, February 28, 2017.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation ("Ophthotech") (NASDAQ: OPHT) between May...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Ophthotech Corporation (NASDAQ:OPHT) securities...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Ophthotech Corporation (Nasdaq:OPHT) today announced that it has initiated a plan to review its strategic alternatives in order to maximize shareholder value.
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Ophthotech Corporation (NASDAQGS: OPHT) in the U.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
When you seek to find the right structure or combination, you can get hurt.
The Dow posts a record close with the S&P 500 lower, while tech stocks dragged on the Nasdaq as Wall Street looks to a Fed decision on interest rates Tuesday.
The Dow rises but pares gains as Wall Street looks to a Fed decision on interest rates later in the week.
Levi & Korsinsky, LLP announces that it has commenced an investigation of Ophthotech Corporation ("Ophthotech" or the "Company") (NASDAQ:OPHT) concerning possible violations of federal securities laws by the Company...
Here's a technical look on how to trade some of the most active stocks on the market this week.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks are mixed Monday as oil prices surge after non-OPEC countries agree to cut production and markets anticipate Fed moves.
Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.
Shares of Ophthotech are plunging after the company's Phase 3 results failed to meet specific endpoints.
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
Ophthotech Corporation (Nasdaq:OPHT) today announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating...
Investors in Ophthotech Corp saw new options become available today, for the January 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Ophthotech Corporation (Nasdaq: OPHT) today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company's business and product development programs.
Ophthotech Corporation (Nasdaq:OPHT) today announced that the Phase 2b study results of Fovista ® (pegpleranib), the Company's anti-PDGF agent administered in combination with Lucentis ® (ranibizumab) anti-VEGF...
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its third quarter financial results on Tuesday, November 8, 2016.